arrow
W

Wolfgang R. Sperr

Medical University of Vienna
H指数:97
被引数:3.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Identification of Homing Receptors and Activation-Linked Surface Antigens on Human Mast Cells and Basophils

鉴定人肥大细胞和嗜碱性粒细胞上的归巢受体及活化相关表面抗原

2026-10-130
OAAI
Triterpenoid Exposure and HO-1 Blockade Sensitize Neoplastic Mast Cells Against Midostaurin and Avapritinib

三萜暴露和HO-1阻断使肿瘤性肥大细胞对米多司他汀和阿瓦普利替尼更敏感

Cells
IF5.2
2026-01-010
OA
Tyrosine kinase inhibitors are associated with reduced AML transformation in systemic mastocytosis with myeloid neoplasm

酪氨酸激酶抑制剂与伴有髓系肿瘤的系统性肥大细胞增生症中AML转化的减少相关

Blood
IF23.1
2026-01-010
OAAI
Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetoclax plus hypomethylating agents: a real-world, multicentric study

缩短维奈克拉暴露后AML患者接受维奈克拉联合去甲基化药物治疗的疗效评估:一项真实世界、多中心研究

2025-10-220
OA
Changes in cardiac parameters during venetoclax treatment

在venetoclax治疗期间的心脏参数变化

2025-10-010
OAAI
Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts

健康与疾病中的组织驻留髓系和组织细胞:新兴概念

2025-09-120
PREAI
Comparing functional and genomic-based precision medicine in blood cancer patients

比较基于功能与基因组学的血液肿瘤患者精准医学

2025-04-240
OAAI
Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
2024-12-012
OAAI
Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma

双重特异性STAT3/5降解剂有效阻断急性髓系白血病和自然杀伤/T细胞淋巴瘤

2024-11-280
OAAI
Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study
2024-08-070
OAAI
Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
2024-06-052
OAAI
Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry
2024-04-234
PRE
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT

基线类胰蛋白酶的正常范围应为1至15 ng/mL,并涵盖患有h α t的健康个体

2023-10-0122
OAAI